You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response
|
|---|---|
| Published in |
Breast Cancer Research, May 2015
|
| DOI | 10.1186/s13058-015-0582-3 |
| Pubmed ID | |
| Authors |
Mark Jesus M. Magbanua, Denise M. Wolf, Christina Yau, Sarah E. Davis, Julia Crothers, Alfred Au, Christopher M. Haqq, Chad Livasy, Hope S. Rugo, I-SPY 1 TRIAL Investigators, Laura Esserman, John W. Park, Laura J. van ’t Veer |
| Abstract |
The molecular biology involving neoadjuvant chemotherapy (NAC) response is poorly understood. To elucidate the impact of NAC on breast cancer transcriptome and its association with clinical outcome, we analyzed gene expression data from serial tumor samples of breast cancer patients who received NAC in the I-SPY 1 TRIAL. Expression data were collected before treatment (T1), 24-96 h after initiation of chemotherapy (T2) and at surgery (TS). Expression between T1vsT2 (N = 36) and T1vsTS (N = 39) were compared. Subtype was assigned using PAM50. Differences in early gene expression changes (T2-T1) between responders and non-responders as defined by residual cancer burden (RCB) were evaluated. Cox proportional hazards modeling was used to identify genes in residual tumors associated with recurrence-free survival (RFS). Pathway analysis was performed with Ingenuity® software. Comparing expression profiles at T1vsT2 and T1vsTS detected significantly altered expression of 150 and 59 transcripts, respectively. We observed notable down-regulation of proliferation and immune-related genes at T2. Lower concordance in subtype assignment was observed between T1vsTS (62 %) as compared to T1vsT2 (75 %). Analysis of early gene expression changes (T2-T1) revealed that decreased expression of cell cycle inhibitors was associated with poor response. Increased interferon signaling (TS-T1) and high expression of cell proliferation genes in residual tumors (TS) were associated with reduced RFS. Serial gene expression analysis revealed candidate immune and proliferation pathways associated with response and recurrence. Larger studies incorporating the approach described here are warranted to identify predictive and prognostic biomarkers in the NAC setting for specific targeted therapies. The I-SPY 1 TRIAL was registered on April 9, 2002 as NCT00033397 . |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 89 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Chile | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 86 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 27% |
| Student > Ph. D. Student | 19 | 21% |
| Student > Master | 7 | 8% |
| Student > Bachelor | 7 | 8% |
| Student > Postgraduate | 5 | 6% |
| Other | 14 | 16% |
| Unknown | 13 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 30% |
| Agricultural and Biological Sciences | 21 | 24% |
| Biochemistry, Genetics and Molecular Biology | 8 | 9% |
| Immunology and Microbiology | 4 | 4% |
| Engineering | 3 | 3% |
| Other | 11 | 12% |
| Unknown | 15 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2015.
All research outputs
#19,944,994
of 25,374,647 outputs
Outputs from Breast Cancer Research
#1,655
of 2,053 outputs
Outputs of similar age
#191,749
of 279,492 outputs
Outputs of similar age from Breast Cancer Research
#32
of 37 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,053 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,492 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.